NCT05107856 - PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions

Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromesMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma

Interventions

DRUG

PRT1419

PRT1419 will be administered by intravenous infusion

DRUG

Azacitidine

Azacitidine will be administered by intravenous or subcutaneous

DRUG

Venetoclax

Venetoclax will be administered orally

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center - Main Campus, New York

11776

North Shore Hematology Oncology Associates. DBA New York Cancer and Blood Specialists, Port Jefferson Station

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

20817

American Oncology Partners of Maryland, PA, Bethesda

32763

Mid Florida Hematology and Oncology Center, Orange City

32804

AdventHealth Bone and Marrow Transplant Center, Orlando

44718

Gabrail Cancer Center Research, Canton

77030

The University of Texas MD Anderson Cancer Center, Houston

08724

New Jersey Center for Cancer Research, Brick